Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...

The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...

If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability ...

Sanofi, one of the world’s largest pharmaceutical companies, has acquired the Serbian biopharmaceutical company Dren Bio for ...

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...

Nathan Mammen and Cole Tipton of Snell & Wilmer LLP address the question as to how AI could affect or even upend determining ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Monday, March 24, 2025. Let’s take ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals ...

The Goldman Sachs Group started coverage on shares of Sanofi (NASDAQ:SNY – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The firm issued a neutral ...

Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

This health education program aims to help patients living with COPD experience better health outcomes and improved quality ...